These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
591 related articles for article (PubMed ID: 15319032)
21. Molecular correction of Duchenne muscular dystrophy by splice modulation and gene editing. Hanson B; Wood MJA; Roberts TC RNA Biol; 2021 Jul; 18(7):1048-1062. PubMed ID: 33472516 [TBL] [Abstract][Full Text] [Related]
22. Bubble liposomes and ultrasound exposure improve localized morpholino oligomer delivery into the skeletal muscles of dystrophic mdx mice. Negishi Y; Ishii Y; Shiono H; Akiyama S; Sekine S; Kojima T; Mayama S; Kikuchi T; Hamano N; Endo-Takahashi Y; Suzuki R; Maruyama K; Aramaki Y Mol Pharm; 2014 Mar; 11(3):1053-61. PubMed ID: 24433046 [TBL] [Abstract][Full Text] [Related]
23. Exploring the frontiers of therapeutic exon skipping for Duchenne muscular dystrophy by double targeting within one or multiple exons. Aartsma-Rus A; Kaman WE; Weij R; den Dunnen JT; van Ommen GJ; van Deutekom JC Mol Ther; 2006 Sep; 14(3):401-7. PubMed ID: 16753346 [TBL] [Abstract][Full Text] [Related]
24. By-passing the nonsense mutation in the 4 CV mouse model of muscular dystrophy by induced exon skipping. Mitrpant C; Fletcher S; Iversen PL; Wilton SD J Gene Med; 2009 Jan; 11(1):46-56. PubMed ID: 19006096 [TBL] [Abstract][Full Text] [Related]
26. Exon Skipping Therapy Using Phosphorodiamidate Morpholino Oligomers in the mdx52 Mouse Model of Duchenne Muscular Dystrophy. Miyatake S; Mizobe Y; Takizawa H; Hara Y; Yokota T; Takeda S; Aoki Y Methods Mol Biol; 2018; 1687():123-141. PubMed ID: 29067660 [TBL] [Abstract][Full Text] [Related]
27. Multiexon skipping leading to an artificial DMD protein lacking amino acids from exons 45 through 55 could rescue up to 63% of patients with Duchenne muscular dystrophy. Béroud C; Tuffery-Giraud S; Matsuo M; Hamroun D; Humbertclaude V; Monnier N; Moizard MP; Voelckel MA; Calemard LM; Boisseau P; Blayau M; Philippe C; Cossée M; Pagès M; Rivier F; Danos O; Garcia L; Claustres M Hum Mutat; 2007 Feb; 28(2):196-202. PubMed ID: 17041910 [TBL] [Abstract][Full Text] [Related]
37. Effective exon skipping and dystrophin restoration by 2'-o-methoxyethyl antisense oligonucleotide in dystrophin-deficient mice. Yang L; Niu H; Gao X; Wang Q; Han G; Cao L; Cai C; Weiler J; Yin H PLoS One; 2013; 8(4):e61584. PubMed ID: 23658612 [TBL] [Abstract][Full Text] [Related]
38. Target selection for antisense oligonucleotide induced exon skipping in the dystrophin gene. Errington SJ; Mann CJ; Fletcher S; Wilton SD J Gene Med; 2003 Jun; 5(6):518-27. PubMed ID: 12797117 [TBL] [Abstract][Full Text] [Related]
39. Design of 2'-O-Me RNA/ENA chimera oligonucleotides to induce exon skipping in dystrophin pre-mRNA. Takagi M; Yagi M; Ishibashi K; Takeshima Y; Surono A; Matsuo M; Koizumi M Nucleic Acids Symp Ser (Oxf); 2004; (48):297-8. PubMed ID: 17150596 [TBL] [Abstract][Full Text] [Related]
40. Exons 45-55 Skipping Using Antisense Oligonucleotides in Immortalized Human DMD Muscle Cells. He M; Yokota T Methods Mol Biol; 2023; 2640():313-325. PubMed ID: 36995604 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]